Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Nov:86:358-363.
doi: 10.1016/j.ejca.2017.09.032. Epub 2017 Nov 5.

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma

Birgit Geoerger  1 , Christophe Bergeron  2 , Lia Gore  3 , Leonard Sender  4 , Ira J Dunkel  5 , Cynthia Herzog  6 , Lieve Brochez  7 , Ofelia Cruz  8 , Karsten Nysom  9 , Elmer Berghorn  10 , Burcin Simsek  10 , Jun Shen  10 , Alberto Pappo  11
Affiliations
Clinical Trial

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma

Birgit Geoerger et al. Eur J Cancer. 2017 Nov.

Abstract

Background: Ipilimumab is approved for the treatment of advanced melanoma in adults; however, little information on the efficacy and safety of ipilimumab in younger patients is available.

Methods: Patients aged 12 to <18 years with previously treated or untreated, unresectable stage III or IV malignant melanoma received ipilimumab 3 or 10 mg/kg every 3 weeks. Primary end-points were 1-year overall survival and safety.

Results: Over a period of 3.5 years, 12 patients received ipilimumab at either 3 mg/kg (n = 4) or 10 mg/kg (n = 8). The median number of ipilimumab doses was four for 3 mg/kg and three for 10 mg/kg. At 1 year, three of four patients on 3 mg/kg and five of eight patients on 10 mg/kg were alive. Two patients on 10 mg/kg had partial response, and one on 3 mg/kg had stable disease. One patient had durable partial response at 3 years without further treatment, at time of this report. There was one grade 3/4 immune-mediated adverse reaction with 3 mg/kg and five with 10 mg/kg. There were no treatment-related deaths. The study was stopped due to slow accrual.

Conclusions: At >1 year follow-up, ipilimumab demonstrated activity in melanoma patients aged 12 to <18 years, with a similar safety profile as that seen in adults. Our trial highlights the difficulties of enrolling younger patients with rare diseases in clinical trials for treatments that are approved in adults, suggesting adolescents with cancer types occurring predominantly in adults should be considered for inclusion in adult trials of promising new drugs.

Clinical trial registration: NCT01696045.

Keywords: Adolescents; Advanced melanoma; Immune-mediated adverse reaction; Ipilimumab; Overall survival; Progression-free survival.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources